LON:IMM ImmuPharma (IMM) Share Price, News & Analysis GBX 3.20 -0.30 (-8.43%) As of 09/15/2026 12:29 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsNews and Trends About ImmuPharma Stock (LON:IMM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImmuPharma alerts:Sign Up Key Stats Today's Range 3.02▼ 3.6050-Day Range 3.21▼ 4.5052-Week Range 3.02▼ 18.90Volume3.80 million shsAverage Volume2.48 million shsMarket Capitalization£20.00 millionP/E RatioN/ADividend Yield0.77%Price TargetN/AConsensus RatingN/A Company Overview ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. Read More Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMM Stock News HeadlinesImmuPharma Reports £1.1 Million Operating Loss as P140 and Kapiglucagon Programmes AdvanceSeptember 15 at 6:06 AM | uk.finance.yahoo.comImmuPharma appoints Kymos as third Kapiglucagon partner in build towards clinicAugust 10, 2026 | uk.finance.yahoo.comYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type of finance to build lasting wealth. Legendary investor Joel Greenblatt calls it 'the closest thing to a perpetual motion machine you will ever see.' One investor famously turned 50000 dollars into 900 million using this approach. Porter Stansberry breaks down its origins and mechanics in a new free documentary. | Porter & Company (Ad)ImmuPharma selects Kymos to support Kapiglucagon diabetes development programmeAugust 10, 2026 | uk.finance.yahoo.comThermo Fisher (TMO) Lands ImmuPharma Kapiglucagon Diabetes Manufacturing RoleJuly 24, 2026 | finance.yahoo.comImmuPharma appoints Bachem to manufacture key ingredient for diabetes drugJune 25, 2026 | uk.finance.yahoo.comImmuPharma flags Murcia research into P140 as potential brain cancer treatmentJune 24, 2026 | uk.finance.yahoo.comImmuPharma focused on securing P140 licensing deal in 2026May 28, 2026 | uk.finance.yahoo.comSee More Headlines IMM Stock Analysis - Frequently Asked Questions How have IMM shares performed this year? ImmuPharma's stock was trading at GBX 6.20 at the start of the year. Since then, IMM shares have decreased by 48.3% and is now trading at GBX 3.21. How were ImmuPharma's earnings last quarter? ImmuPharma plc (LON:IMM) posted its earnings results on Tuesday, September, 15th. The company reported ($0.84) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative trailing twelve-month return on equity of 353.21%. How do I buy shares of ImmuPharma? Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ImmuPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), 4D pharma (DDDD), Thor Energy (THR), Aminex (AEX) and GSK (GSK). Company Calendar Today9/15/2026Last Earnings9/15/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:IMM CIKN/A Webwww.immupharma.org Phone+44-20-71524080FaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£2.51 million Net Margins3,519.56% Pretax MarginN/A Return on Equity-353.21% Return on Assets-43.00% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.16 per share Price / Cash Flow20.50 Book ValueGBX 0.65 per share Price / Book4.97Miscellaneous Outstanding Shares623,911,000Free FloatN/AMarket Cap£20.00 million OptionableNot Optionable Beta3.01 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (LON:IMM) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
